Raleigh Capital Management Inc. Cytom X Therapeutics, Inc. Transaction History
Raleigh Capital Management Inc.
- $253 Million
- Q4 2024
A detailed history of Raleigh Capital Management Inc. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 250 shares of CTMX stock, worth $172. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$172
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
46.1MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$5.05 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$3.61 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$3.56 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$2.69 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$2.22 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $45.5M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...